Overview

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Status:
RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment in patients with advanced stage BTC.

Phase:

PHASE1

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

AstraZeneca
Private Philanthropic Funds

Treatments:

durvalumab
Peptides
poly ICLC
tremelimumab